Overview: Macrolide Immunosuppressants
- 1 July 1993
- journal article
- Published by Taylor & Francis in Current Opinion on Therapeutic Patents
- Vol. 3 (7) , 931-949
- https://doi.org/10.1517/13543776.3.7.931
Abstract
(1993). Overview: Macrolide Immunosuppressants. Current Opinion on Therapeutic Patents: Vol. 3, No. 7, pp. 931-949. doi: 10.1517/13543776.3.7.931This publication has 68 references indexed in Scilit:
- The mechanism of action of cyclosporin A and FK506Published by Elsevier ,2003
- Inhibition of Neutrophil Chemokinesis on Vitronectin by Inhibitors of CalcineurinScience, 1992
- Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cellsBiochemical and Biophysical Research Communications, 1992
- Leukocyte chemotactic activity of FKBP and inhibition by FK506Biochemical and Biophysical Research Communications, 1992
- cDNA Cloning of a human 5 kDa FK506 and rapamycin binding proteinBiochemical and Biophysical Research Communications, 1992
- Mécanismes moléculaires de l'action des agents immunosuppresseursmédecine/sciences, 1992
- Rapamycin: FK506's fraternal twin or distant cousin?Immunology Today, 1991
- PRECLINICAL EVALUATION OF A NEW POTENT IMMUNOSUPPRESSIVE AGENT, RAPAMYCINTransplantation, 1991
- TOXICITY OF RAPAMYCIN—A COMPARATIVE AND COMBINATION STUDY WITH CYCLOSPORINE AT IMMUNOTHERAPEUTIC DOSAGE IN THE RATTransplantation, 1991
- FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitroAnti-Cancer Drugs, 1991